Eli Lilly and Company Target of Unusually High Options Trading (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) saw some unusual options trading activity on Friday. Stock traders acquired 52,076 call options on the company. This represents an increase of 29% compared to the typical volume of 40,231 call options.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: European regulators backed expanded use of Jaypirca in CLL, potentially enlarging Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Lilly outlined Medicare GLP-1 Bridge access for Foundayo and Zepbound, reinforcing investor confidence in the company’s obesity growth engine. Article Title
• Positive Sentiment: The company’s obesity and diabetes pipeline remains a bullish theme, with recent clinical updates and strong market enthusiasm keeping sentiment constructive. Article Title
• Positive Sentiment: Unusual call-option activity suggests traders are positioning for further upside in LLY.
• Positive Sentiment: Recent reports highlighted Lilly as a momentum favorite and a potential beneficiary of broader investor enthusiasm for healthcare stocks.
• Neutral Sentiment: Lilly updated a donanemab Alzheimer’s study to test annual dosing, which keeps attention on its neuroscience pipeline but does not yet change fundamentals. Article Title
• Neutral Sentiment: Lilly ended an early-stage prostate cancer combination trial, which appears to be a portfolio cleanup rather than a major setback. Article Title
• Negative Sentiment: Some insider and institutional holdings data show heavy selling in recent months, though this is being outweighed today by product and regulatory optimism.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Norges Bank acquired a new position in Eli Lilly and Company in the 4th quarter worth about $12,976,634,000. Capital Research Global Investors boosted its stake in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. J. Stern & Co. LLP grew its holdings in shares of Eli Lilly and Company by 46,191.3% during the fourth quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock worth $4,047,245,000 after purchasing an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. increased its stake in shares of Eli Lilly and Company by 876.1% in the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after buying an additional 2,131,734 shares during the period. Finally, Fifth Third Bancorp increased its stake in shares of Eli Lilly and Company by 321.3% in the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after buying an additional 1,497,423 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent research reports. Jefferies Financial Group raised their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Bank of America increased their target price on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 6th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Finally, Barclays increased their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,235.07.

Eli Lilly and Company Price Performance

NYSE LLY traded up $81.88 during trading on Friday, hitting $1,209.57. 3,829,481 shares of the company’s stock were exchanged, compared to its average volume of 3,200,347. The company has a market cap of $1.14 trillion, a PE ratio of 42.92, a P/E/G ratio of 1.22 and a beta of 0.53. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,208.18. The stock’s 50 day moving average price is $1,030.27 and its two-hundred day moving average price is $1,019.65.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts expect that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.